Results 1 to 10 of about 6,539 (200)

Transcriptomics reveals new regulatory mechanisms involved in benralizumab response [PDF]

, 2023
[EN] Benralizumab, a monoclonal antibody targeting IL5RA, significantly improves asthma symptoms and quality of life in severe asthmatic patients. However, understanding the factors influencing treatment response remains a challenge.
Dávila González, Ignacio Jesús, Estravís Sastre, Miguel, García Sánchez, María Asunción, Gil Melcón, María, Gómez‐García, Manuel, Isidoro García, María, Martín García, Cristina, Moreno‐Jimenez, Emma, Morgado, Natalia, Muñoz Bellido, Francisco Javier, Pérez Pazos, Jacqueline, Ramos González, Jacinto, Sanz Lozano, Catalina Sofía, Triviño, Juan Carlos   +13 more
core   +1 more source

Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma [PDF]

, 2019
Objetivo: Mepolizumab está indicado como tratamiento adicional del asma eosinofílica refractaria grave. Las diferencias observadas en subgrupos poblacionales según recuento eosinofílico plasmático, existencia de pacientes con altos niveles de ...
Alarcón de la Lastra Romero, Catalina, Alegre del Rey, Emilio Jesús, García Mochón, Leticia, Gil Sierra, Manuel David, Sánchez Hidalgo, Marina   +4 more
core   +3 more sources

Benralizumab treatment in an elderly patient with eosinophilic esophagitis resulted in remission: a case report

BMC Geriatrics
Background Interleukin-5 (IL-5) has recently been shown to play a crucial role in eosinophil-mediated diseases, implying that an IL-5 receptor alpha chain (IL-5Rα) antibody (benralizumab) can be effective against eosinophilic esophagitis (EoE).
Azusa Ishii, Tomofumi Shibata, Yohei Tsunoda, Takafumi Kayukawa, Masahiro Kobayashi, Masami Orinaka, Shoko Miyamatsu, Yoshio Ryuge, Shuichi Asano, Ichidai Tanaka   +9 more
doaj   +1 more source

A prospective study exploring the predictors of response to benralizumab in patients with refractory bronchial asthma

Fujita Medical Journal, 2022
Objective: This study aimed to evaluate the predictors of response to benralizumab therapy in patients with refractory bronchial asthma. Methods: After 16 weeks of benralizumab therapy, 32 patients with refractory bronchial asthma were assigned to two
Masahiro Hirose, Kazunobu Kuwabara, Rieko Kondo, Takahiko Horiguchi   +3 more
doaj   +1 more source

Longitudinal stability of asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) study [PDF]

, 2016
BACKGROUND: Asthma is a biologically heterogeneous disease and development of novel therapeutics requires understanding of pathophysiologic phenotypes. There is uncertainty regarding the stability of clinical characteristics and biomarkers in asthma over
C. Porsbjerg, D. Singh, E. S. Barnathan, F. Baribaud, J. M. FitzGerald, J. N. Kline, M. J. Loza, M. Laviolette, null null, P. Berger, P. Chanez, P. E. Silkoff, P. O. Girodet, S. Kelsen, S. Khatri, V. Backer, V. S. Susulic   +16 more
core   +1 more source

Real-life effects of benralizumab on airway oscillometry in severe eosinophilic asthma

BMJ Open Respiratory Research, 2023
Introduction Eosinophil depletion with benralizumab reduces exacerbations and improves disease control and FEV1 in patients with severe eosinophilic asthma. However, few studies have investigated the effect of biologics on small airways dysfunction (SAD)
Brian J Lipworth, Rory Chan
doaj   +1 more source

Dupilumab efficacy in uncontrolled, moderate-to-severe asthma with self-reported chronic rhinosinusitis [PDF]

, 2019
BACKGROUND: Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for IL-4 and IL-13 signaling, key drivers of type 2 inflammation.
Castro, Mario, et al,, Maspero, Jorge F
core   +1 more source

Characteristics of patients with severe, uncontrolled, eosinophilic asthma enrolled in a French cohort

Journal of Asthma and Allergy, 2018
Michel Aubier,1–4 Gabriel Thabut,1–3,5 Caroline Fabry-Vendrand6 1Inserm UMR1152, Physiopathology and Epidemiology of Respiratory Diseases, Paris, France; 2Faculty of Medicine, Paris Diderot University, Paris, France; 3Laboratory of Excellence,
Aubier M, Thabut G, Fabry-Vendrand C
doaj  

Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study

Frontiers in Immunology, 2023
BackgroundEosinophilic granulomatosis with polyangiitis (EGPA) is a rare vasculitis characterized by asthma, systemic manifestations, and blood and tissue eosinophilia.ObjectiveTo assess the effectiveness and safety of mepolizumab (anti-IL-5) and ...
Santi Nolasco, Santi Nolasco, Andrea Portacci, Raffaele Campisi, Enrico Buonamico, Corrado Pelaia, Alida Benfante, Massimo Triggiani, Giuseppe Spadaro, Maria Filomena Caiaffa, Giulia Scioscia, Aikaterini Detoraki, Giuseppe Valenti, Francesco Papia, Alessandra Tomasello, Nunzio Crimi, Nicola Scichilone, Girolamo Pelaia, Giovanna Elisiana Carpagnano, Claudia Crimi, Claudia Crimi   +20 more
doaj   +1 more source

Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma

, 2019
Systemic/oral corticosteroids (OCS) have been used for decades in the management of acute asthma exacerbations and chronically in patients with uncontrolled severe asthma.
Bousquet, Jean, Brusselle, Guy, Buhl, Roland, Katsaounou, Paraskevi, Martinez, Rafael, Pfister, Pascal, Wahn, Ulrich   +6 more
core   +1 more source